APA

Yakes F. M., Chen J., Tan J., Yamaguchi K., Shi Y., Yu P., Qian F., Chu F., Bentzien F., Cancilla B., Orf J., You A., Laird A. D., Engst S., Lee L., Lesch J., Chou Y. & Joly A. H. (20120511). Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. : Molecular cancer therapeutics.

Chicago

Yakes F Michael, Chen Jason, Tan Jenny, Yamaguchi Kyoko, Shi Yongchang, Yu Peiwen, Qian Fawn, Chu Felix, Bentzien Frauke, Cancilla Belinda, Orf Jessica, You Andrew, Laird A Douglas, Engst Stefan, Lee Lillian, Lesch Justin, Chou Yu-Chien and Joly Alison H. 20120511. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. : Molecular cancer therapeutics.

Harvard

Yakes F. M., Chen J., Tan J., Yamaguchi K., Shi Y., Yu P., Qian F., Chu F., Bentzien F., Cancilla B., Orf J., You A., Laird A. D., Engst S., Lee L., Lesch J., Chou Y. and Joly A. H. (20120511). Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. : Molecular cancer therapeutics.

MLA

Yakes F Michael, Chen Jason, Tan Jenny, Yamaguchi Kyoko, Shi Yongchang, Yu Peiwen, Qian Fawn, Chu Felix, Bentzien Frauke, Cancilla Belinda, Orf Jessica, You Andrew, Laird A Douglas, Engst Stefan, Lee Lillian, Lesch Justin, Chou Yu-Chien and Joly Alison H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. : Molecular cancer therapeutics. 20120511.